Search results for "FRAM"

showing 10 items of 2142 documents

Replication and extension of framing effects to compliance with health behaviors during pandemics

2021

Outbreaks of infectious diseases represent a significant challenge for health authorities around the world Public cooperation and compliance with health recommendations constitute critical steps to stop the spread of such diseases But how should these recommendations be framed to achieve the most desirable outcomes? Across two experiments, we show that the classic Asian Disease Problem (Tversy and Kahneman, 1981) is replicable, regardless of disease type (real vs hypothetical) Thus, people are less (vs more) willing to take risks when information is positively (negatively) framed, irrespective of disease type, although they are generally more risk-averse in real pandemics Furthermore, peopl…

medicine.medical_specialty0211 other engineering and technologiesReplication02 engineering and technologyDiseasePsycINFOCompliance (psychology)Swine fluEmotionality021105 building & constructionPandemicmedicineCOVID-19 ; Replication ; Framing ; Swine flu ; Health behavior0501 psychology and cognitive sciencesHealth behaviorSafety Risk Reliability and Quality050107 human factorsPublic health05 social sciencesPublic Health Environmental and Occupational HealthOutbreakFraming effectFramingCovid-19PsychologySafety ResearchSocial psychologySafety Science
researchProduct

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

2017

SummaryExisting clinical scores do not perform well in predicting bleeding in elderly patients with acute venous thromboembolism (VTE). We sought to derive an easy-to-use clinical score to help physicians identify elderly patients with VTE who are at high-risk of bleeding during extended anticoagulation (>3 months). Our derivation sample included 743 patients aged ≥65 years with VTE who were enrolled in a prospective multicenter cohort study. All patients received extended anticoagulation with vitamin K antagonists. We derived our score using competing risk regression, with the time to a first major bleeding up to 36 months of extended anticoagulation as the outcome, and 17 candidate var…

medicine.medical_specialtyAnemia2720 Hematology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciencesAnticoagulation0302 clinical medicineElderlyInternal medicineAnticoagulation; Bleeding risk; Elderly; HematologyBleeding riskmedicineDerivation030212 general & internal medicineInternal validation610 Medicine & healthddc:616Framingham Risk Scorebusiness.industry10031 Clinic for AngiologyCancerHematologymedicine.diseaseSurgery10209 Clinic for CardiologybusinessVenous thromboembolismMajor bleeding360 Social problems & social servicesCohort study
researchProduct

Head-to-head comparison of contemporary heart failure risk scores.

2021

Altres ajuts: acords transformatius de la UAB Aims: Several heart failure (HF) web-based risk scores are currently used in clinical practice. Currently, we lack head-to-head comparison of the accuracy of risk scores. This study aimed to assess correlation and mortality prediction performance of Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC-HF) risk score, which includes clinical variables + medications; Seattle Heart Failure Model (SHFM), which includes clinical variables + treatments + analytes; PARADIGM Risk of Events and Death in the Contemporary Treatment of Heart Failure (PREDICT-HF) and Barcelona Bio-Heart Failure (BCN-Bio-HF) risk calculator, which also include biomarke…

medicine.medical_specialtyCalibration (statistics)Head to headHeart failureSpearman's rank correlation coefficientRisk AssessmentCorrelationRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineRisk modelsHumansOverall performanceMortalityNatriuretic PeptidesHeart FailureFramingham Risk Scorebusiness.industrymedicine.diseasePrognosisRisk predictionPeptide FragmentsClinical PracticeHeart failureCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean journal of heart failureReferences
researchProduct

Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analys…

2017

People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients (N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had significantly higher o…

medicine.medical_specialtyCardiovascular disease; bipolar disorder; cerebrovascular disease; congestive heart failure; coronary heart disease; major depression; premature mortality; schizophrenia; severe mental illness03 medical and health sciences0302 clinical medicinesevere mental illnessMedicineCardiovascular disease severe mental illness schizophrenia bipolar disorder major depression coronary heart disease cerebrovascular disease congestive heart failure premature mortalitycoronary heart diseasePsychiatrybipolar disorderFramingham Risk Scorebusiness.industryVascular diseaseIncidence (epidemiology)Hazard ratioCorrectionOdds ratiomedicine.diseaseCardiovascular disease030227 psychiatrycerebrovascular diseaseschizophreniaPsychiatry and Mental healthcongestive heart failurepremature mortalityHeart failureMajor depressive disorderPshychiatric Mental Healthbusinessmajor depressionBody mass index030217 neurology & neurosurgery
researchProduct

Impact of the COVID-19 pandemic on hospitalizations for acute coronary syndromes: a multinational study

2021

Abstract Background COVID-19 has challenged the health system organization requiring a fast reorganization of diagnostic/therapeutic pathways for patients affected by time-dependent diseases such as acute coronary syndromes (ACS). Aim To describe ACS hospitalizations, management, and complication rate before and after the COVID-19 pandemic was declared. Design Ecological retrospective study. Methods: We analyzed aggregated epidemiological data of all patients > 18 years old admitted for ACS in twenty-nine hub cardiac centers from 17 Countries across 4 continents, from December 1st, 2019 to April 15th, 2020. Data from December 2018 to April 2019 were used as historical period. Results…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Adolescent[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologyRate ratio03 medical and health sciences0302 clinical medicineInternal medicinePandemicEpidemiologymedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromePandemicsRetrospective StudiesOriginal PaperFramingham Risk Scorebusiness.industrySARS-CoV-2COVID-19Retrospective cohort studyGeneral Medicinemedicine.diseaseConfidence intervalHospitalizationbusinessAcademicSubjects/MED00010
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

Subclinical atrial fibrillation: how hard should we look?

2012

More than three decades ago, an analysis from the Framingham Heart Study revealed that atrial fibrillation (AF) increases the risk of stroke by a factor of five in non-rheumatic AF and by a factor of 17 in rheumatic AF.1 Since then, it has convincingly been shown that anticoagulation is one of the most effective secondary stroke prophylactic treatment options, which reduces the risk of stroke by 2/3,2 even in an older population.3 AF may occur in different types and in an individual patient often starts with paroxysmal AF, but later becomes persistent or permanent AF.4 Interestingly, the risk of stroke or systemic embolism is influenced by cardiovascular risk factors such as hypertension, d…

medicine.medical_specialtyDisease030204 cardiovascular system & hematologyGlobal HealthAsymptomatic03 medical and health sciences0302 clinical medicineFramingham Heart StudyRisk FactorsInternal medicineAtrial FibrillationmedicineHumansClinical significancecardiovascular diseasesStrokeSubclinical infectionAgedbusiness.industryIncidenceCardiac Pacing ArtificialAnticoagulantsAtrial fibrillationmedicine.diseasePrognosis3. Good healthStrokeCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryAtrial flutterHeart (British Cardiac Society)
researchProduct

Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program

2020

Diabetes is associated with a substantially increased risk of all-cause death, mainly driven by cardiovascular (CV) mortality. Furthermore, diabetes is associated with poorer outcomes after acute myocardial infarction (AMI) (1). Impaired glomerular filtration rate (GFR) is also associated with an increased risk of CV mortality (2). However, whether diabetes still confers a higher risk of mortality in patients with impaired GFR remains unknown. The aim of this study was to assess the long-term prognostic significance of both diabetes and renal impairment in two prospective nationwide cohorts of AMI patients: FAST-MI (French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarc…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Renal function030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIntensive careInternal MedicinemedicineRisk of mortality030212 general & internal medicineMyocardial infarction10. No inequalityComputingMilieux_MISCELLANEOUSAdvanced and Specialized NursingFramingham Risk Scorebusiness.industrymedicine.disease3. Good healthHeart failureCardiologybusinessKidney disease
researchProduct

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month…

2017

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time. RESULTS: Altho…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineInternal MedicinemedicineGlycemicFramingham Risk Scorebusiness.industryLiraglutideBrief ReportInsulinDiabetesLiraglutideCardiovascular riskmedicine.diseaseliraglutide diabetesMetforminEndocrinologyBlood pressureVisceral adipositybusinessmedicine.drug
researchProduct

Differences in cardiac structure and function between black and white patients: Another step in the evaluation of cardiovascular risk in chronic kidn…

2017

medicine.medical_specialtyEuropean Continental Ancestry Group030232 urology & nephrologyMEDLINE030204 cardiovascular system & hematologyLeft ventricular hypertrophyWhite PeopleCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCardiovascular DiseaseInternal MedicinemedicineHumansCardiac structureRenal Insufficiency ChronicFramingham Risk ScoreWhite (horse)business.industryRisk Factormedicine.diseaseCardiovascular DiseasesCardiologyOriginal ArticleCohort StudiebusinessCohort studyKidney diseaseHuman
researchProduct